iSpecimen Inc. (ISPC): Nasdaq/NYSE listing notice — iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum

iSpecimen Inc.

Received Nasdaq notice on May 29, 2026 for non-compliance with minimum stockholders' equity of $2.5M; equity was $814,038.
Company has 45 calendar days to submit a compliance plan to Nasdaq; if accepted, may get up to 180-day extension.
Trading of common stock (ISPC) continues on Nasdaq Capital Market with no immediate effect.
Company intends to submit a plan but warns no assurance Nasdaq will accept or that compliance will be regained.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

iSpecimen Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May 29, 2026, the Company doe

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-063575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.